Nov, 4, 2008 – Medizone International, Inc. Announces Consulting Relationship with TDV Global, Inc.
Medizone International, Inc. (MZEI.PK) Announces Strategic Consulting Relationship with TDV Global, Inc.
SAN FRANCISCO,CALIFORNIA. November 4, 2008 - TDV Global (TDVGlobal.com) is a highly professional and experienced strategic management consulting firm. Approximately 70% of their business involves consulting for government agencies and projects, the remainder for private enterprise, mostly in the Health and Security medical fields. TDV Global has assisted Medizone with the founding of its' recently established non-profit affiliate, The Canadian Foundation for Global Health (CFGH). Mr. Brad Goble, the President of TDV Global, has been appointed an officer and member of the Board of Directors of the Canadian Foundation for Global Health. Additionally, the offices for the CFGH are being located at TDV Global in Ottawa. Working with Dr. Michael E. Shannon of Medizone International, TDV Global has also played a key role in producing the product development plan for Medizone's Hospital Sterilization Initiative.
Edwin Marshall, Chairman of the Board and CEO of Medizone commented; "Over the past ten years, Dr. Shannon has successfully worked on many different projects with Mr. Goble and his firm. Between the hospital sterilization initiative and founding the CFGH, Medizone has been working with TDV Global since mid-September. I could not be more pleased with the results so far. Given their many current health related activities involving G-8 countries, TDV will assist Medizone in strategically aligning us with government and institutional interests in Canada, the US and Europe. We welcome TDV Global as a vital and strategic partner."
Medizone International, Inc., is a research and development stage company engaged in the development of patented and unpatented technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions. It is currently developing technology to decontaminate and sterilize hospital surgical suites, emergency rooms and intensive care units.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.